Skip to main content
. 2024 Mar 26;41(5):276–282. doi: 10.1136/emermed-2023-213824

Table 4.

Adverse event by type

Intervention
(n=484)
Control
(n=488)
Serious adverse events (≥1)*, n (%) 25 (5.2%) 25 (5.1%)
Adverse events (≥1), n (%)
Throat/mouth irritation (extreme) 10 (3.2%) 8 (2.7%)
n=310 n=293
Dry cough (extreme) 13 (4.2%) 12 (4.1%)
n=310 n=292

*All serious adverse events resulting in hospitalisation over the study period.